A Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection
Open Access
- 1 August 2012
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 80 (8), 2678-2688
- https://doi.org/10.1128/iai.00215-12
Abstract
The global emergence of Clostridium difficile infection (CDI) has contributed to the recent surge in severe antibiotic-associated diarrhea and colonic inflammation. C. difficile produces two homologous glucosylating exotoxins, TcdA and TcdB, both of which are pathogenic and require neutralization to prevent disease occurrence. However, because of their large size and complex multifunctional domain structures, it has been a challenge to produce native recombinant toxins that may serve as vaccine candidates. Here, we describe a novel chimeric toxin vaccine that retains major neutralizing epitopes from both toxins and confers complete protection against primary and recurrent CDI in mice. Using a nonpathogenic Bacillus megaterium expression system, we generated glucosyltransferase-deficient holotoxins and demonstrated their loss of toxicity. The atoxic holotoxins induced potent antitoxin neutralizing antibodies showing little cross-immunogenicity or protection between TcdA and TcdB. To facilitate simultaneous protection against both toxins, we generated an active clostridial toxin chimera by switching the receptor binding domain of TcdB with that of TcdA. The toxin chimera was fully cytotoxic and showed potent proinflammatory activities. This toxicity was essentially abolished in a glucosyltransferase-deficient toxin chimera, cTxAB. Parenteral immunization of mice or hamsters with cTxAB induced rapid and potent neutralizing antibodies against both toxins. Complete and long-lasting disease protection was conferred by cTxAB vaccinations against both laboratory and hypervirulent C. difficile strains. Finally, prophylactic cTxAB vaccination prevented spore-induced disease relapse, which constitutes one of the most significant clinical issues in CDI. Thus, the rational design of recombinant chimeric toxins provides a novel approach for protecting individuals at high risk of developing CDI.Keywords
This publication has 54 references indexed in Scilit:
- Systemic Dissemination of Clostridium difficile Toxins A and B Is Associated With Severe, Fatal Disease in Animal ModelsThe Journal of Infectious Diseases, 2011
- Mouse Relapse Model of Clostridium difficile InfectionInfection and Immunity, 2011
- Immunization with Bacillus Spores Expressing Toxin A Peptide Repeats Protects against Infection with Clostridium difficile Strains Producing Toxins A and BInfection and Immunity, 2011
- Structural organization of the functional domains of Clostridium difficile toxins A and BProceedings of the National Academy of Sciences of the United States of America, 2010
- Piglet Models of Acute or ChronicClostridium difficileIllnessThe Journal of Infectious Diseases, 2010
- An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxinsJournal of Microbiological Methods, 2009
- A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin AVaccine, 2009
- Antibody-Enhanced, Fc Gamma Receptor-Mediated Endocytosis of Clostridium difficile Toxin AInfection and Immunity, 2009
- Toxin B is essential for virulence of Clostridium difficileNature, 2009
- Transcutaneous Immunization withClostridium difficileToxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in MiceInfection and Immunity, 2007